APOE e4 is known to enhance Aß accumulation in AD patients [44], trigger inflammation cascades [45], aggravate tau pathology and potentiate tau-mediated neurodegeneration, which is associated with accelerated neurodegeneration [3], possibly leading to higher needs for healthcare services. This evidence concerns the gene MAPT and Alzheimer disease.